/
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology ( ENHANZE ) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous ( SC ) delivery of injected drugs and fluids…
$77.81
+$0.27 (+0.35%)
EOD Jul 17, 2026
Margins and capital returns are both well above average: 33.58% operating margin, ROIC at 15.46%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 37.6%, still solid. Margins contracted 20.7pp, which offsets some of the top-line progress.
At 27x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 24.94% to 15.46%, capital efficiency is deteriorating.
27.3x earnings, 14.3x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.51B
▲ +37.6% YoY
Net Income (TTM)
$349M
▼ -28.6% YoY
Op. Margin
33.94%
▼ -20.7pp YoY
ROIC
16.75%
▼ -9.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$668M
▲ +37.6% YoY
Op. Cash Flow (TTM)
$677M
▲ +36.0% YoY
Net Debt
$1.86B
Cash & Equiv.
$319M
5Y CAGR: +39.2%
5Y CAGR: +64.8%
Continue Research
At a P/E of 27.3 and a price-to-free-cash-flow of 14.3, Halozyme Therapeutics (HALO) trades below a two-stage DCF intrinsic value of about $222.18 per share, so at $77.81 the stock looks undervalued (185.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Halozyme Therapeutics scores 68/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $222.18 per share for HALO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $166.64. At today's $77.81, that puts the stock about 185.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Halozyme Therapeutics scores 68 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 33.9% operating margin and a 16.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. HALO currently trades below its estimated intrinsic value and scores 68/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.